Lubka T Roumenina

List of Publications by Year in Descending Order

110 papers	6,313 citations	39 h-index	79 g-index
131 ext. papers	8,090 ext. citations	6.5 avg, IF	5.81 L-index

#	Paper	IF	Citations
110	Coagulome and the tumor microenvironment: an actionable interplay.. *Trends in Cancer*, **2022**,	12.5	5
109	C1q+ macrophages: passengers or drivers of cancer progression.. *Trends in Cancer*, **2022**,	12.5	2
108	Test for Measuring Complement Attack on Endothelial Cells: From Research to Bedside.. *Frontiers in Immunology*, **2022**, 13, 860689	8.4	1
107	B cells and cancer: To B or not to B?. *Journal of Experimental Medicine*, **2021**, 218,	16.6	25
106	Ex Vivo Complement Activation on Endothelial Cells: Research and Translational Value. *Trends in Molecular Medicine*, **2021**, 27, 418-421	11.5	1
105	Intracellular Factor H Drives Tumor Progression Independently of the Complement Cascade. *Cancer Immunology Research*, **2021**, 9, 909-925	12.5	7
104	Complement C1s and C4d as Prognostic Biomarkers in Renal Cancer: Emergence of Noncanonical Functions of C1s. *Cancer Immunology Research*, **2021**, 9, 891-908	12.5	7
103	Case Report: Adult Post-COVID-19 Multisystem Inflammatory Syndrome and Thrombotic Microangiopathy. *Frontiers in Immunology*, **2021**, 12, 680567	8.4	8
102	Factor D Inhibition Blocks Complement Activation Induced by Mutant Factor B Associated With Atypical Hemolytic Uremic Syndrome and Membranoproliferative Glomerulonephritis. *Frontiers in Immunology*, **2021**, 12, 690821	8.4	0
101	Chronic histiocytic intervillositis: manifestation of placental alloantibody-mediated rejection. *American Journal of Obstetrics and Gynecology*, **2021**, 225, 662.e1-662.e11	6.4	1
100	Heme induces human and mouse platelet activation through C-type-lectin-like receptor-2. *Haematologica*, **2021**, 106, 626-629	6.6	20
99	Complement activation is a crucial driver of acute kidney injury in rhabdomyolysis. *Kidney International*, **2021**, 99, 581-597	9.9	15
98	Plasma C3d levels as a diagnostic marker for complete complement factor I deficiency. *Journal of Allergy and Clinical Immunology*, **2021**, 147, 749-753.e2	11.5	0
97	The receptor for advanced glycation end products is a sensor for cell-free heme. *FEBS Journal*, **2021** , 288, 3448-3464	5.7	5
96	The Benefits of Complement Measurements for the Clinical Practice. *Methods in Molecular Biology*, **2021**, 2227, 1-20	1.4	1
95	Detection of Anti-C3b Autoantibodies by ELISA. *Methods in Molecular Biology*, **2021**, 2227, 133-139	1.4	
94	Complement Detection in Human Tumors by Immunohistochemistry and Immunofluorescence. *Methods in Molecular Biology*, **2021**, 2227, 191-203	1.4	2

93	Complement C3 Deposition on Endothelial Cells Revealed by Flow Cytometry. *Methods in Molecular Biology*, **2021**, 2227, 97-105	1.4	
92	Heme Oxygenase 1: A Defensive Mediator in Kidney Diseases. *International Journal of Molecular Sciences*, **2021**, 22,	6.3	5
91	Complement factor H: a guardian within?. *Kidney International*, **2021**, 100, 747-749	9.9	1
90	Terminal complement without C5 convertase?. *Blood*, **2021**, 137, 431-432	2.2	0
89	Complement System: Promoter or Suppressor of Cancer Progression?. *Antibodies*, **2020**, 9,	7	13
88	B cells and complement at the forefront of chemotherapy. *Nature Reviews Clinical Oncology*, **2020**, 17, 393-394	19.4	2
87	Anti-Factor B Antibodies and Acute Postinfectious GN in Children. *Journal of the American Society of Nephrology: JASN*, **2020**, 31, 829-840	12.7	20
86	Circulating FH Protects Kidneys From Tubular Injury During Systemic Hemolysis. *Frontiers in Immunology*, **2020**, 11, 1772	8.4	5
85	Analysis of protein missense alterations by combining sequence- and structure-based methods. *Molecular Genetics & Genomic Medicine*, **2020**, 8, e1166	2.3	16
84	Complement activation in sickle cell disease: Dependence on cell density, hemolysis and modulation by hydroxyurea therapy. *American Journal of Hematology*, **2020**, 95, 456-464	7.1	19
83	The murine Microenvironment Cell Population counter method to estimate abundance of tissue-infiltrating immune and stromal cell populations in murine samples using gene expression. *Genome Medicine*, **2020**, 12, 86	14.4	17
82	Hemopexin as an Inhibitor of Hemolysis-Induced Complement Activation. *Frontiers in Immunology*, **2020**, 11, 1684	8.4	8
81	Clinical and functional consequences of anti-properdin autoantibodies in patients with lupus nephritis. *Clinical and Experimental Immunology*, **2020**, 201, 135-144	6.2	2
80	Glomerulonephritis With Isolated C3 Deposits as a Manifestation of Subtotal Factor I Deficiency. *Kidney International Reports*, **2019**, 4, 1354-1358	4.1	0
79	Tumor Cells Hijack Macrophage-Produced Complement C1q to Promote Tumor Growth. *Cancer Immunology Research*, **2019**, 7, 1091-1105	12.5	68
78	Anti-inflammatory activity of intravenous immunoglobulin through scavenging of heme. *Molecular Immunology*, **2019**, 111, 205-208	4.3	8
77	P-selectin drives complement attack on endothelium during intravascular hemolysis in TLR-4/heme-dependent manner. *Proceedings of the National Academy of Sciences of the United States of America*, **2019**, 116, 6280-6285	11.5	51
76	Complement activation during intravascular hemolysis: Implication for sickle cell disease and hemolytic transfusion reactions. *Transfusion Clinique Et Biologique*, **2019**, 26, 116-124	1.9	19

75	Autoantibodies Against C3b-Functional Consequences and Disease Relevance. *Frontiers in Immunology*, **2019**, 10, 64	8.4	14
74	Context-dependent roles of complement in cancer. *Nature Reviews Cancer*, **2019**, 19, 698-715	31.3	99
73	The role of Complement in Post-Transfusion Hemolysis and Hyperhemolysis Reaction. *Transfusion Medicine Reviews*, **2019**, 33, 225-230	7.4	5
72	Hemolysis Derived Products Toxicity and Endothelium: Model of the Second Hit. *Toxins*, **2019**, 11,	4.9	23
71	Hemolytic uremic syndrome associated with Bordetella pertussis infection in a 2-month-old infant carrying a pathogenic variant in complement factor H. *Pediatric Nephrology*, **2019**, 34, 533-537	3.2	3
70	Endothelium structure and function in kidney health and disease. *Nature Reviews Nephrology*, **2019**, 15, 87-108	14.9	149
69	Detection of Autoantibodies to Complement Components by Surface Plasmon Resonance-Based Technology. *Methods in Molecular Biology*, **2019**, 1901, 271-280	1.4	4
68	Site-specific N-glycosylation analysis of soluble Fc□receptor IIIb in human serum. *Scientific Reports*, **2018**, 8, 2719	4.9	18
67	Characterization of Renal Injury and Inflammation in an Experimental Model of Intravascular Hemolysis. *Frontiers in Immunology*, **2018**, 9, 179	8.4	24
66	Intravascular hemolysis activates complement via cell-free heme and heme-loaded microvesicles. *JCI Insight*, **2018**, 3,	9.9	87
65	ATYPICAL HEMOLYTIC UREMIC SYNDROME AND C3 GLOMERULOPATHY: CONCLUSIONS FROM A «KIDNEY DISEASE: IMPROVING GLOBAL OUTCOMES» (KDIGO) CONTROVERSIES CONFERENCE. *Nephrology (Saint-Petersburg)*, **2018**, 22, 18-39	0.4	
64	Complement C3 is a novel modulator of the anti-factor VIII immune response. *Haematologica*, **2018**, 103, 351-360	6.6	13
63	FP076ATYPICAL HEMOLYTIC UREMIC SYNDROME - WHY THE KIDNEY?. *Nephrology Dialysis Transplantation*, **2018**, 33, i74-i74	4.3	
62	A Single-Domain Antibody Targeting Complement Component C5 Acts as a Selective Inhibitor of the Terminal Pathway of the Complement System and Thus Functionally Mimicks the C-Terminal Domain of the SSL7 Protein. *Frontiers in Immunology*, **2018**, 9, 2822	8.4	4
61	Heme Drives Susceptibility of Glomerular Endothelium to Complement Overactivation Due to Inefficient Upregulation of Heme Oxygenase-1. *Frontiers in Immunology*, **2018**, 9, 3008	8.4	23
60	Both Monoclonal and Polyclonal Immunoglobulin Contingents Mediate Complement Activation in Monoclonal Gammopathy Associated-C3 Glomerulopathy. *Frontiers in Immunology*, **2018**, 9, 2260	8.4	21
59	Anti-Factor B and Anti-C3b Autoantibodies in C3 Glomerulopathy and Ig-Associated Membranoproliferative GN. *Journal of the American Society of Nephrology: JASN*, **2017**, 28, 1603-1613	12.7	56
58	Functional and structural insight into properdin control of complement alternative pathway amplification. *EMBO Journal*, **2017**, 36, 1084-1099	13	40

57	Heme-Exposed Pooled Therapeutic IgG Improves Endotoxemia Survival. *Inflammation*, **2017**, 40, 117-122	5.1	3
56	C5 nephritic factors drive the biological phenotype of C3 glomerulopathies. *Kidney International*, **2017**, 92, 1232-1241	9.9	52
55	A novel CFHR1-CFHR5 hybrid leads to a familial dominant C3 glomerulopathy. *Kidney International*, **2017**, 92, 876-887	9.9	29
54	A Familial C3GN Secondary to Defective C3 Regulation by Complement Receptor 1 and Complement Factor H. *Journal of the American Society of Nephrology: JASN*, **2016**, 27, 1665-77	12.7	29
53	Endothelial cells: source, barrier, and target of defensive mediators. *Immunological Reviews*, **2016**, 274, 307-329	11.3	63
52	Heme: Modulator of Plasma Systems in Hemolytic Diseases. *Trends in Molecular Medicine*, **2016**, 22, 200-213	11.5	81
51	Intravenous Immunoglobulin with Enhanced Polyspecificity Improves Survival in Experimental Sepsis and Aseptic Systemic Inflammatory Response Syndromes. *Molecular Medicine*, **2016**, 21, 1002-1010	6.2	16
50	Von Willebrand Factor Interacts with Surface-Bound C1q and Induces Platelet Rolling. *Journal of Immunology*, **2016**, 197, 3669-3679	5.3	16
49	Mechanism and functional implications of the heme-induced binding promiscuity of IgE. *Biochemistry*, **2015**, 54, 2061-72	3.2	11
48	Anti-factor H autoantibodies in C3 glomerulopathies and in atypical hemolytic uremic syndrome: one target, two diseases. *Journal of Immunology*, **2015**, 194, 5129-38	5.3	73
47	Loss of DGK induces endothelial cell activation and death independently of complement activation. *Blood*, **2015**, 125, 1038-46	2.2	63
46	Mapping interactions between complement C3 and regulators using mutations in atypical hemolytic uremic syndrome. *Blood*, **2015**, 125, 2359-69	2.2	79
45	C3dg-CR3 interaction in erythrophagocytosis. *Blood*, **2015**, 126, 828-9	2.2	1
44	Complement System Part II: Role in Immunity. *Frontiers in Immunology*, **2015**, 6, 257	8.4	501
43	Complement System Part I - Molecular Mechanisms of Activation and Regulation. *Frontiers in Immunology*, **2015**, 6, 262	8.4	714
42	Distal Angiopathy and Atypical Hemolytic Uremic Syndrome: Clinical and Functional Properties of an Anti-Factor H IgA Antibody. *American Journal of Kidney Diseases*, **2015**, 66, 331-6	7.4	14
41	Functional Characterization of Autoantibodies against Complement Component C3 in Patients with Lupus Nephritis. *Journal of Biological Chemistry*, **2015**, 290, 25343-55	5.4	31
40	The interaction between factor H and VWF increases factor H cofactor activity and regulates VWF prothrombotic status. *Blood*, **2014**, 123, 121-5	2.2	54

39	Complement factor B mutations in atypical hemolytic uremic syndrome-disease-relevant or benign?. *Journal of the American Society of Nephrology: JASN*, **2014**, 25, 2053-65	12.7	74
38	Functional evaluation of factor H genetic and acquired abnormalities: application for atypical hemolytic uremic syndrome (aHUS). *Methods in Molecular Biology*, **2014**, 1100, 237-47	1.4	13
37	Anti-factor H autoantibodies assay. *Methods in Molecular Biology*, **2014**, 1100, 249-56	1.4	9
36	Antibody polyreactivity in health and disease: statu variabilis. *Journal of Immunology*, **2013**, 191, 993-9	5.3	74
35	Complement factor H related proteins (CFHRs). *Molecular Immunology*, **2013**, 56, 170-80	4.3	159
34	An engineered construct combining complement regulatory and surface-recognition domains represents a minimal-size functional factor H. *Journal of Immunology*, **2013**, 191, 912-21	5.3	54
33	Eculizumab in an anephric patient with atypical haemolytic uraemic syndrome and advanced vascular lesions. *Nephrology Dialysis Transplantation*, **2013**, 28, 2899-907	4.3	21
32	Physiological and therapeutic complement regulators in kidney transplantation. *Current Opinion in Organ Transplantation*, **2013**, 18, 421-9	2.5	11
31	Complement activation by heme as a secondary hit for atypical hemolytic uremic syndrome. *Blood*, **2013**, 122, 282-92	2.2	155
30	Renal transplantation under prophylactic eculizumab in atypical hemolytic uremic syndrome with CFH/CFHR1 hybrid protein. *American Journal of Transplantation*, **2012**, 12, 1938-44	8.7	61
29	Use of eculizumab for atypical haemolytic uraemic syndrome and C3 glomerulopathies. *Nature Reviews Nephrology*, **2012**, 8, 643-57	14.9	392
28	Exploration du compl□ment : actualit□ 2012. *Revue Francophone Des Laboratoires*, **2012**, 2012, 31-37	0	1
27	Identification of a major linear C1q epitope allows detection of systemic lupus erythematosus anti-C1q antibodies by a specific peptide-based enzyme-linked immunosorbent assay. *Arthritis and Rheumatism*, **2012**, 64, 3706-14		28
26	A prevalent C3 mutation in aHUS patients causes a direct C3 convertase gain of function. *Blood*, **2012**, 119, 4182-91	2.2	107
25	Genetics of hemolytic uremic syndromes. *Presse Medicale*, **2012**, 41, e105-14	2.2	26
24	Acquired and genetic complement abnormalities play a critical role in dense deposit disease and other C3 glomerulopathies. *Kidney International*, **2012**, 82, 454-64	9.9	360
23	Overall neutralization of complement factor H by autoantibodies in the acute phase of the autoimmune form of atypical hemolytic uremic syndrome. *Journal of Immunology*, **2012**, 189, 3528-37	5.3	78
22	Complement alternative pathway acts as a positive feedback amplification of neutrophil activation. *Blood*, **2011**, 117, 1340-9	2.2	142

21	Alternative complement pathway assessment in patients with atypical HUS. *Journal of Immunological Methods*, **2011**, 365, 8-26	2.5	119
20	Functional complement C1q abnormality leads to impaired immune complexes and apoptotic cell clearance. *Journal of Immunology*, **2011**, 187, 4369-73	5.3	47
19	Mutations in complement regulatory proteins predispose to preeclampsia: a genetic analysis of the PROMISSE cohort. *PLoS Medicine*, **2011**, 8, e1001013	11.6	204
18	Heme interacts with c1q and inhibits the classical complement pathway. *Journal of Biological Chemistry*, **2011**, 286, 16459-69	5.4	42
17	Pregnancy-associated hemolytic uremic syndrome revisited in the era of complement gene mutations. *Journal of the American Society of Nephrology: JASN*, **2010**, 21, 859-67	12.7	320
16	Atypical hemolytic uremic syndrome associated with mutations in complement regulator genes. *Seminars in Thrombosis and Hemostasis*, **2010**, 36, 641-52	5.3	37
15	A human FVIII inhibitor modulates FVIII surface electrostatics at a VWF-binding site distant from its epitope. *Journal of Thrombosis and Haemostasis*, **2010**, 8, 1524-31	15.4	11
14	Kinetics and thermodynamics of interaction of coagulation factor VIII with a pathogenic human antibody. *Molecular Immunology*, **2009**, 47, 290-7	4.3	5
13	Hyperfunctional C3 convertase leads to complement deposition on endothelial cells and contributes to atypical hemolytic uremic syndrome. *Blood*, **2009**, 114, 2837-45	2.2	119
12	Interaction of the globular domain of human C1q with Salmonella typhimurium lipopolysaccharide. *Biochimica Et Biophysica Acta - Proteins and Proteomics*, **2008**, 1784, 1271-6	4	26
11	Complement C1q-target proteins recognition is inhibited by electric moment effectors. *Journal of Molecular Recognition*, **2007**, 20, 405-15	2.6	25
10	Iron ions and haeme modulate the binding properties of complement subcomponent C1q and of immunoglobulins. *Scandinavian Journal of Immunology*, **2007**, 65, 230-9	3.4	25
9	Antibodies use heme as a cofactor to extend their pathogen elimination activity and to acquire new effector functions. *Journal of Biological Chemistry*, **2007**, 282, 26696-26706	5.4	62
8	C1q and its growing family. *Immunobiology*, **2007**, 212, 253-66	3.4	143
7	Interaction of C1q with IgG1, C-reactive protein and pentraxin 3: mutational studies using recombinant globular head modules of human C1q A, B, and C chains. *Biochemistry*, **2006**, 45, 4093-104	3.2	108
6	Existence of different but overlapping IgG- and IgM-binding sites on the globular domain of human C1q. *Biochemistry*, **2006**, 45, 9979-88	3.2	35
5	Contribution of the C1q Polypeptide Chains in the Recognition of CRP. *Biotechnology and Biotechnological Equipment*, **2005**, 19, 122-125	1.6	
4	Role of Ca2+ in the electrostatic stability and the functional activity of the globular domain of human C1q. *Biochemistry*, **2005**, 44, 14097-109	3.2	43

3	Mutational analyses of the recombinant globular regions of human C1q A, B, and C chains suggest an essential role for arginine and histidine residues in the C1q-IgG interaction. *Journal of Immunology*, **2004**, 172, 4351-8	5.3	58
2	Registration of the Interaction Between C1q Human Complement Derivatives and Immunoglobulins by Elisa:Role of the Solid Phase. *Biotechnology and Biotechnological Equipment*, **2004**, 18, 116-120	1.6	
1	The murine Microenvironment Cell Population counter method to estimate abundance of tissue-infiltrating immune and stromal cell populations in murine samples using gene expression		1